Biological synthesis of nicotinamide mononucleotide.
Level 5 - mechanism / opinion, no new human data
Narrative review of enzymatic and bioprocess engineering methods with no primary clinical or experimental trial data (CEBM Level 5 by design analogy).
PubMed 34626279 · doi:10.1007/s10529-021-03191-1
What was done
The authors reviewed biological synthetic routes for producing nicotinamide mononucleotide (NMN). The review examined enzymatic pathways, key intermediate generation—specifically phosphoribosyl diphosphate (PRPP) from substrates like ribose, adenosine, and xylose—the action of nicotinamide phosphoribosyltransferase (Nampt), ATP regeneration systems, and reaction condition regulations.
What was found
The abstract reports no numerical yield, efficiency, or cost figures. It qualitatively describes that biological NMN production primarily proceeds via PRPP conversion by Nampt. Because generating PRPP requires ATP, incorporating ATP regeneration systems helps diminish overall ATP consumption during biocatalysis. Regulating enzymes outside the direct synthetic chain is also highlighted as necessary for optimizing production.
Why it matters
Because chemical synthesis of NMN faces challenges with isomeric complexity, mapping viable biological synthesis pathways and reducing high-cost cofactor (ATP) consumption is critical for scalable manufacturing.
Limits
No quantitative yields, titers, reaction kinetics, or benchmark comparisons are reported in the abstract. As a narrative review, it provides no original experimental data or clinical assessment.
Cited by
- contradicts NAMPT converts NMN into NAD in a single enzymatic step, and NAMPT expression increases under cellular stress and caloric restriction.